Theseus Pharmaceuticals, Inc. Common Stock
THRX
THRX was delisted on the 13th of February, 2024.
1 hedge funds and large institutions have $0 invested in Theseus Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 69 closing their positions.
99% less funds holding
Funds holding: 70 → 1 (-69)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $146M → $0 (-$146M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 69
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$53.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$71.7M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
-$16.6M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$13.2M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$8.58M |
| 5 |
BlackRock
New York
|
-$5.77M |
THRX Hedge Fund Activity: Q1 2024 in Review
1 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) for Q1 2024, worth a combined $0 — down 100% from $146M a quarter earlier.
Sellers outnumbered buyers: 69 funds closed out of THRX and 0 opened new positions — a net loss of 69 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Goldman Sachs, adding an estimated $53.8K. The largest seller was OrbiMed, exiting entirely with an estimated $71.7M sold.
- 1 institutional investor held Theseus Pharmaceuticals, Inc. Common Stock (THRX) as of Q1 2024, down from 70 in Q4 2023.
- Funds reported $0 of Theseus Pharmaceuticals, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Theseus Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 69 closed out, a net change of -69 holders.
- The largest Theseus Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Goldman Sachs, an estimated $53.8K added.
- The largest Theseus Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was OrbiMed, an estimated $71.7M sold.
Based on aggregated 13F filings for Q1 2024.